Amanote Research

Amanote Research

    RegisterSign In

Cannabidiol Drug Approved for Use in Two Forms of Epilepsy

Pharmacy Today
doi 10.1016/j.ptdy.2018.08.013
Full Text
Open PDF
Abstract

Available in full text

Date

September 1, 2018

Authors
Rachel Balick
Publisher

Elsevier BV


Related search

From the FDA: Epilepsy Drug Approved

Journal of the American Osteopathic Association, The
MedicineAlternative MedicineComplementary
1994English

Cannabidiol: FDA Approved New Drug for the Lennox-Gastaut Syndrome and Dravet Syndrome: Pharmacotherapeutics Review

NeuroPharmac Journal
2019English

Cannabidiol as a Treatment for Epilepsy

Journal of Neurology
Neurology
2017English

Cannabidiol in Patients With Treatment-Resistant Epilepsy

The Lancet Neurology
Neurology
2016English

Cannabidiol for Treatment of Childhood Epilepsy–A Cross-Sectional Survey

Frontiers in Neurology
Neurology
2018English

Second RNAi Drug Approved

Nature Biotechnology
Applied MicrobiologyBiotechnologyBiomedical EngineeringMolecular MedicineBioengineering
2020English

Unique Treatment Potential of Cannabidiol for the Prevention of Relapse to Drug Use: Preclinical Proof of Principle

Neuropsychopharmacology
PsychiatryMental HealthPharmacology
2018English

Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome

New England Journal of Medicine
Medicine
2017English

One Drug for Epilepsy.

BMJ
1978English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy